Who Owns Activase?

Roche publishes an annual sustainability report disclosing environmental performance, social metrics, and governance practices. Roche has committed to achieving carbon neutrality across its own operations (Scopes 1 and 2) by 2025 and net-zero emissions across its value chain by 2050.

Genentech's manufacturing sites in South San Francisco operate under environmental management systems certified to ISO 14001. Roche's pharmaceutical manufacturing processes are subject to strict regulatory oversight by the FDA, EMA, and other health authorities, which establishes a baseline of manufacturing quality and environmental compliance.

Roche is a signatory to the UN Global Compact and reports against its ten principles annually. The company participates in the Pharmaceutical Supply Chain Initiative, which promotes responsible sourcing practices among pharmaceutical manufacturers.

Access to medicines is an ongoing ethical issue for Activase. The drug's price in the United States has historically been high relative to comparable products in other markets. Genentech maintains patient assistance programs for eligible uninsured or underinsured patients.

Activase's development was recognized as a landmark achievement in recombinant DNA biotechnology. The drug was among the earliest FDA-approved recombinant biologics and helped establish Genentech as a pioneering biotechnology company.

The development of alteplase as a treatment for acute ischemic stroke has been cited in medical literature as a significant advance in emergency neurology. No specific branded product awards for Activase are documented in independent third-party records as of May 2025. Recognition for alteplase as a clinical tool is reflected in its inclusion in international stroke treatment guidelines published by the American Heart Association, the European Stroke Organisation, and equivalent bodies.

Pricing Controversy (1987 to present): At its 1987 launch, Activase was priced at approximately 2,200 USD per treatment course, making it substantially more expensive than the then-standard thrombolytic streptokinase. The pricing generated significant controversy in medical and health policy circles and prompted congressional hearings. Pricing of alteplase has remained a subject of health policy debate in the United States, with the drug costing several thousand dollars per treatment as of 2025. In countries with national health systems, alteplase is priced under negotiated formulary agreements at substantially lower levels.

Clinical Controversy: GUSTO Trial and Heart Attack Indication (1990s): The GUSTO trial published in 1993 compared alteplase to streptokinase for acute myocardial infarction and found a modest survival benefit for alteplase at a substantially higher cost. This triggered an extensive health economics debate about whether the marginal benefit justified the cost differential. The subsequent emergence of primary percutaneous coronary intervention (PCI) as a superior treatment for heart attacks reduced alteplase's use in cardiac indications significantly over the following two decades.

Biosimilar Competition: Alteplase is a biologic drug, meaning that biosimilar versions require a dedicated FDA approval pathway under the Biologics Price Competition and Innovation Act. As of May 2025, no biosimilar version of alteplase had received FDA approval. Roche and Genentech have defended the regulatory exclusivity of Activase through this pathway.

No Safety Recalls: Activase has not been subject to any FDA-mandated product recall as of May 2025. The drug carries an FDA-required Warnings and Precautions section describing risks of bleeding, including intracranial hemorrhage, which is disclosed in its prescribing information.